WS Investor
25 Aug 2026, 17:36
Johnson & Johnson Wins FDA Approval for IMAAVY in First-Ever wAIHA Treatment
Johnson & Johnson (NYSE: JNJ) received a major regulatory win after the U.S. Food and Drug Administration approved IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia, or wAIHA, in adults and patients aged 12 and older who are currently or were previously treated with corticosteroids. It is the first FDA-approved therapy specifically for the rare and potentially life-threatening disease.
Why the FDA Approval Matters
Warm autoimmune hemolytic anemia occurs when pathogenic IgG autoantibodies attack and destroy red blood cells, potentially causing severe anemia and debilitating fatigue. Previous treatment options were largely corticosteroids and immunosuppressants, which broadly suppress the immune system rather than specifically targeting the disease-driving antibodies.
IMAAVY takes a more targeted approach. The drug blocks the neonatal Fc receptor, or FcRn, reducing circulating pathogenic IgG antibodies while preserving B-cell function.
The approval was supported by the Phase 2/3 ENERGY study. Approximately three times as many patients receiving the approved IMAAVY dose achieved a durable hemoglobin response compared with placebo at 24 weeks. Patients also showed a mean hemoglobin increase of 1 g/dL as early as Week 1, while fatigue scores improved versus placebo.
IMAAVY Franchise Expands
The approval also broadens the commercial potential of IMAAVY. The drug was previously approved in the U.S. for generalized myasthenia gravis, making wAIHA its second approved indication. Johnson & Johnson is studying nipocalimab across several additional autoantibody-driven diseases.
For Johnson & Johnson, the FDA decision strengthens its immunology portfolio while giving IMAAVY a first-mover position in a disease with significant unmet medical need.
Johnson & Johnson (NYSE: JNJ) received a major regulatory win after the U.S. Food and Drug Administration approved IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia, or wAIHA, in adults and patients aged 12 and older who are currently or were previously treated with corticosteroids. It is the first FDA-approved therapy specifically for the rare and potentially life-threatening disease.
Why the FDA Approval Matters
Warm autoimmune hemolytic anemia occurs when pathogenic IgG autoantibodies attack and destroy red blood cells, potentially causing severe anemia and debilitating fatigue. Previous treatment options were largely corticosteroids and immunosuppressants, which broadly suppress the immune system rather than specifically targeting the disease-driving antibodies.
IMAAVY takes a more targeted approach. The drug blocks the neonatal Fc receptor, or FcRn, reducing circulating pathogenic IgG antibodies while preserving B-cell function.
The approval was supported by the Phase 2/3 ENERGY study. Approximately three times as many patients receiving the approved IMAAVY dose achieved a durable hemoglobin response compared with placebo at 24 weeks. Patients also showed a mean hemoglobin increase of 1 g/dL as early as Week 1, while fatigue scores improved versus placebo.
IMAAVY Franchise Expands
The approval also broadens the commercial potential of IMAAVY. The drug was previously approved in the U.S. for generalized myasthenia gravis, making wAIHA its second approved indication. Johnson & Johnson is studying nipocalimab across several additional autoantibody-driven diseases.
For Johnson & Johnson, the FDA decision strengthens its immunology portfolio while giving IMAAVY a first-mover position in a disease with significant unmet medical need.
